Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

£93 Million Package of Support Announced for UK’s Health Industries

Published: Wednesday, July 31, 2013
Last Updated: Wednesday, July 31, 2013
Bookmark and Share
Innovative business and academic projects will benefit from a new £93.2 million package of support.

The investment includes £25.9 million from Round 3 of the Biomedical Catalyst – a programme of public funding jointly managed by the Medical Research Council (MRC) and the Technology Strategy Board. Five universities and 29 companies will receive investment from the Catalyst.
 
One of the academic-led projects will see University of Newcastle use £1 million of MRC funding for a clinical trial to find out whether a drug developed to treat cancer can be repurposed to treat rheumatoid arthritis (RA) in patients who do not respond to existing treatments. The drug works by targeting a different type of cell from conventional therapies and could therefore succeed where conventional treatments have failed. The drug is being developed by Cyclacel Pharmaceuticals, a University of Dundee spin-out that has received two previous rounds of Biomedical Catalyst funding.
 
Another project led by The University of Manchester will use a £450,000 MRC grant to develop and test a smartphone app to deliver cognitive behavioural therapy (CBT) to people who have experienced a first episode of psychosis. If successful in patient trials, the Actissist app could help patients manage their condition more independently and prevent relapses of psychosis that often require unplanned admission to hospital. This would also lead to significant cost savings for the NHS.
 
As part of the recent Government’s Spending Review in June 2013, it was announced that there will be additional support for the Catalyst. Academic researchers and businesses can continue to apply for additional funding through the MRC and the Technology Strategy Board in Round 4 of the Biomedical Catalyst, which is now open.
 
In a further boost to the biomedical industry, a new £38 million National Biologics Manufacturing Centre (NBMC) will be based in Darlington. The centre, funded through investment announced as part of the life sciences strategy, will be a national base for the manufacturing of biological medicines such as antibodies and vaccines.
 
To complete the package of support, a further £29.3 million of investment in healthcare innovation has been announced through three Technology Strategy Board-led funding competitions. These will support businesses in areas such as stratified medicine and regenerative medicine.
 
Announcing the package of investment, Universities and Science Minister David Willetts said:
“By investing in new technologies now we are maintaining the UK’s position as a world leader for innovation. The biomedical industry is a fast moving, high growth sector and the Catalyst has proven to be extremely successful in supporting new business ideas. This investment further drives forward our life sciences strategy.
 
“The new National Biologics Manufacturing Centre will significantly increase the UK’s manufacturing capability in biologics, keeping us ahead in the global race and strengthening the UK’s position as the location of choice for life sciences companies.”
 
Professor Sir John Savill, Chief Executive of the MRC, said:

“Several of the MRC and Technology Strategy Board awards announced today build on previous MRC funding and this research is now reaching an exciting stage of clinical development. It’s fantastic to see this investment beginning to bear fruit. It clearly demonstrates that the Biomedical Catalyst is fulfilling its goal of providing seamless support from early research in universities through to commercialisation by small and medium-sized companies. We look forward to continuing our successful collaboration with the Technology Strategy Board into round 4 and beyond.”
 
Chief Executive of the Technology Strategy Board, Iain Gray said:

“The Biomedical Catalyst programme has already proved a significant success, providing the support companies need to develop their innovations and solve healthcare challenges.
 
“The projects funded through this latest round of the programme demonstrate both the innovative nature of the UK’s health R&D sector and the success of the programme in identifying projects with strong commercial potential.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genes Essential to Life Discovered
Genes critical for life are discovered in humans and mice as part of large-scale phenotyping study.
Thursday, September 15, 2016
Gene Linked to Hearing Loss Identified
Researchers have identifed a gene associated with age-related hearing loss.
Monday, August 22, 2016
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
Monday, August 22, 2016
Discovery of Key Component of HIV Yields New Drug Target
Scientists from the MRC Laboratory of Molecular Biology in Cambridge and University College London have discovered an essential feature of HIV that the virus uses to infect cells whilst avoiding detection by the immune system. This discovery presents a new drug target and the opportunity to re-evaluate existing treatments for HIV to improve their efficacy.
Thursday, August 11, 2016
MRC Technology, Alzheimer’s Association Collaborate
MRC Technology (MRCT), an independent medical research charity based in London, and the Alzheimer’s Association in Chicago have entered into an agreement to review and monitor the Association’s grant-funded research portfolio.
Thursday, January 21, 2016
Study Shows Blocking Brain Inflammation Could Help Alzheimer's
The research was jointly funded by the Medical Research Council (MRC) and Alzheimer’s Research UK.
Saturday, January 09, 2016
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Wednesday, September 30, 2015
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Wednesday, July 22, 2015
MRC, GSK and Five Leading UK Universities Collaborate
Collaboration to crack difficult disease areas.
Thursday, July 16, 2015
‘Mini Bile Ducts’ used to Discover New Drugs that could Prevent Liver Damage
An experimental cystic fibrosis drug has been shown to prevent the disease’s damage to the liver, thanks to a world-first where scientists grew mini bile ducts in the lab.
Tuesday, July 14, 2015
First RNAi Meiosis Screen Reveals Genes Essential to Generate Eggs
Screening techniques developed leading to the discovery of genes essential for meiosis in mammals.
Wednesday, July 08, 2015
Study Identifies New Way to Kill the Malaria Parasite
Scientists have discovered new ways in which the malaria parasite survives in the blood stream of its victims, a discovery that could pave the way to new treatments for the disease.
Tuesday, July 07, 2015
Making Vaccines More Effective In The Elderly
Compound shown to restore the immune system’s inbuilt memory.
Tuesday, November 11, 2014
Immune Organ Regenerated in Mice
Scientists have for the first time used regenerative medicine to fully restore a degenerated organ in a living animal.
Tuesday, April 08, 2014
AstraZeneca, MRC Collaboration to Create New Centre for Early Drug Discovery
The Companies today announced the groundbreaking collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creation of a joint research facility at AstraZeneca’s new R&D centre in Cambridge in the UK.
Monday, March 31, 2014
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
New Discovery May Benefit Farmers Worldwide
Scientists have shown how a crop-microbe 'team' protect against fungal infection.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Protein Studies Discover Molecular Secrets
Two protein studies have mapped proteins that reveal the secrets to recycling carbon and healing cells.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!